NRAS mutations constitute 15–20% of all melanomas and are the most important sub‐group of BRAF WT melanomas, yet therapeutic options for NRAS‐mutant melanoma are still limited (Muñoz‐Couselo et al, 2017). The gene discussed is BRAF; the disease is melanoma.